Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms.
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2013
At a glance
- Drugs LMB 7 (Primary)
- Indications Carcinomatous meningitis
- Focus Adverse reactions
- 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 23 Sep 2005 New trial record.